Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation

Therapeutic Drug Monitoring

Volumn 22, Issue 1, 2000, Pages 14-19

  Shaw, Leslie M ^a,c   Kaplan, Bruce ^b   DeNofrio, David ^a   Korecka, Magdalena ^a   Brayman, Kenneth L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Mycophenolic acid; Renal and heart transplants; Risk of rejection

Indexed keywords

ANTACID AGENT; CYCLOSPORIN; GANCICLOVIR; METRONIDAZOLE; MYCOPHENOLIC ACID; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG MONITORING; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; TRANSPLANTATION;

AREA UNDER CURVE; DRUG INTERACTIONS; DRUG MONITORING; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; MYCOPHENOLIC ACID; TRANSPLANTATION;

EID: 0033981118     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200002000-00003     Document Type: Article

References (33)

1. Sollinger HW, Cho S, Danowitch G, et al. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. The US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995;60:225-32.
2. Keown P, Harry P, Matheu T, et al. A blinded randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996;61:1029-37.
3. Shapiro R, Jordan MI, Scantlebury VP, et al. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/ prednisone/mycophenolate mofetil in renal transplant patients. Transplantation 1999;67:411-15.
4. Takahashi K, Ochaii T, Uchida K, et al. Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. Transplant Proc 1995;27:1421-4
5. Hale MD, Nicholls AJ, Bullingham RES, et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharm Ther 1998;64:672-83.
6. van Gelder T, Hildbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration-controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999;68:261-6.
7. Bullingham RES, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil: a short review. Transplant Proc 1996;28:925-9.
8. Bullingham RES, Nicholls AJ, Kamm BR, Clinical Pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998;34:429-55.
9. Bullingham RES, Shah J, Goldblum R, Schiff M. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis. Br J Clin Phannacol 1996; 41:513-6.
10. Naderer OJ, Dupuis RE, Whiwattanawonga K, et al. Reduction of plasma mycophenolic acid and its glucuronide concentrations with antibiotic treatment. [Abstract] Clin Pharm Ther 1999;65:159.
11. Wolfe F, Mathur V, Tomlanovich S, et al. Pharmacokinetics of mycophenolate mofetil and intravenous gancyclovir alone and in combination in renal transplant patients. Pharmacotherapy 1997; 17:591-8.
12. Shaw LM, Mick R, Nowak I, Korecka M, Brayman KL. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Phannacol 1998;38:268-75.
13. Kaplan B, Friedman G, Malgaonkar S, et al. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol 1999:39:715-20.
14. Weber LT, Shipkova M, Lamensdorf T, et al. Pharmacokinetics of mycophenolic acid and determinants of mycophenolic acid free fraction in pediatric and adult renal transplant patients. J Am Soc Nephrol 1998;9:1511-20.
15. Tsina I, Chu F, Hama K, et al. Manual and automated [robotic] high-performance liquid chromatography methods for the determination of mycophenolic acid and its glucuronide conjugate in plasma. J Chromatogr 1996;675:119-29.
16. Shaw LM, Korecka M, Brayman KL. Pharmacokinetic-pharmacodynamic relationship for mycophenolic acid in renal transplant patients. Graft 1999;2:196-200.
17. Shaw LM, Nicholls A, Hale M, et al. Therapeutic monitoring of mycophenolic acid: A Consensus Panel Report, din Biochem 1998;31:317-22.
18. Schutz E, Armstrong VW, Andreeva M, et al. Limited sampling strategy for the determination of mycophenolic acid AUC in pediatric kidney recipients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Transplant Proc 1998:30:1142-4.
19. Bornhauser M, Schuler U, Porksen G, et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 1999;67: 499-04.
20. DeNofrio D, Loh E, Kao E, et al. Mycophenolic acid concentrations are associated with cardiac allograft rejection [Abstract]. J Heart Lung Transplant 199;18:66.
21. DeNofrio D, Goldberg L, Loh E, et al. Reduced mycophenolic acid concentrations are associated with an increased risk of rejection following heart transplantation [Abstract]. Circulation, in press.
22. Gummert JF, Barten MJ, Wang Y, et al. Therapeutic monitoring of mycophenolic acid: assays of immune function in peripheral blood predict efficacy for inhibition of histologic graft rejection [Abstract]. J Meart Lung Transplant 1999:18:53.
23. Mojarrabi B, Mackenzie PI. Characterization of two UDP glucuronosyltransferases that are predominantly expressed in human colon. Biochem Biophys Res Commun 1998:247:704-9.
24. Kahan BD, Welsh M, Schoenberg L, et al. Variable oral absortion of cyclosporine: a biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation 1996:62:599-606.
25. Fitzsimmons WE, Bekersky I, Dressler D. Demographic considerations in tacrolimus pharmacokinetics. Transplant Proc 1998;30: 1359-64.
26. Tornatore KM, Biocevich DM, Reed KA, et al. Post-transplant diabetes mellitus and methyl prednisolone pharmacokinetics in African-American and Caucasian renal translant recipients. Clin Transplant 1995;9:289-96.
27. Chocair PR, Duley JA, Sabbaga E, et al. Fast and slow methylators: do racial differences influence risk of allograft rejection? Q J Med 1993:86:359-63.
28. Zucker K, Rosen A, Tsaroucha A, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997; 5:225-32.
29. Zucker K, Tsaroucha A, Olson L, et al. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 1999;21:35-43.
30. Smak Gregoor PJH, van Gelder T, Hesse CJ, et al. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporine: a cross sectional study. Nephrol Dial Transplant 1999:14:706-8.
31. Cecka JM, Terasaki PI. Los Angeles, CA, UCLA Tissue Typing Laboratory. Clinical Transplant 1996;8:130;297.
32. Shaw LM, Korecka M, Aradhye S, et al. Impaired renal function, not ethnicity, alters mycophenolic acid pharmacokinetics in African-American renal transplant patients-[Abstract]. Transplantation 1999:67:5623.
33. Haley CJ, Staples MA, Vorpahl J, Wieder-Bunger TA, Jaklitsch AP. Analytical performance of an EMIT assay for mycophenolic acid in plasma [Abstract]. Clin Chem 1997;43:S209.